NCT03697304: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naive and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Any patient who has progressed (with or without achieving benefit) after receiving anti-PD-1 or anti-PD-L1 based treatment is eligible
Exclusions: Patients with known presence of symptomatic central nervous system (CNS) metastases that require treatment – see trial for details; Patients who have received an anti-LAG-3 agent or more than one anti-PD-(L)1-based treatment regimen prior to entering study

Comments are closed.

Up ↑